AdvanTIG-302

Recruiting

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Beigene Study ID info

AdvanTIG-302

ClinicalTrials.gov ID info

China Drug Trials ID info

CTR20211476/CTR20211464

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents